Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750565 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Ethnobridging PK Study in Healthy Subjects
A Phase 1 study of Inflammatory Bowel Diseases and IBD, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03750565: Completed Phase 1 study of Inflammatory Bowel Diseases and IBD, sponsored by Theravance Biopharma.
NCT03750565 is a Phase 1 study of Inflammatory Bowel Diseases and IBD that has completed, run by Theravance Biopharma. The registered enrollment target is 60 participants, below the 42,260-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03750565, a Phase 1 study of Inflammatory Bowel Diseases and IBD, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-1473 - Dose A
- DRUG TD-1473 - Dose B
- DRUG TD-1473 - Dose C
Study Locations (1)
California
- Theravance Biopharma Investigational Site - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 1 |
What the finished NCT03750565 record still lists
NCT03750565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 42,260-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03750565 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03750565 about?
NCT03750565 is a clinical study titled "Multiple Dose Ethnobridging PK Study in Healthy Subjects". A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
What is the current status of trial NCT03750565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-11-27. Estimated completion is 2019-02-13.
What conditions does trial NCT03750565 study?
This clinical trial studies the following conditions: Inflammatory Bowel Diseases, IBD.
What interventions are being tested in trial NCT03750565?
The interventions under investigation include: Placebo (DRUG), TD-1473 - Dose A (DRUG), TD-1473 - Dose B (DRUG), TD-1473 - Dose C (DRUG).
Who is sponsoring clinical trial NCT03750565?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03750565 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03750565's enrollment target sits among peer trials
60 30th of 48 higher than 16 of 48 other Inflammatory Bowel Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammatory Bowel Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
COMPLETED · Phase 1
-
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
COMPLETED · Phase 1
-
Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI